Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN-deficient human fibroblasts

Aging Cell. 2014 Jun;13(3):573-5. doi: 10.1111/acel.12190. Epub 2014 Feb 5.

Abstract

Werner syndrome (WS), caused by mutations at the WRN helicase gene, is a progeroid syndrome characterized by multiple features consistent with accelerated aging. Aberrant double-strand DNA damage repair leads to genomic instability and reduced replicative lifespan of somatic cells. We observed increased autophagy in WRN knockdown cells; this was further increased by short-term rapamycin treatment. Long-term rapamycin treatment resulted in improved growth rate, reduced accumulation of DNA damage foci and improved nuclear morphology; autophagy markers were reduced to near-normal levels, possibly due to clearance of damaged proteins. These data suggest that protein aggregation plays a role in the development of WS phenotypes and that the mammalian target of rapamycin complex 1 pathway is a potential therapeutic target of WS.

Keywords: DNA damage; Werner syndrome; autophagy; mammalian target of rapamycin; rapamycin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Cycle / drug effects
  • Cell Growth Processes / drug effects
  • DNA Damage / drug effects*
  • Exodeoxyribonucleases / deficiency*
  • Fibroblasts / cytology
  • Fibroblasts / drug effects*
  • Fibroblasts / metabolism
  • Humans
  • RecQ Helicases / deficiency*
  • Sirolimus / pharmacology*
  • Werner Syndrome / genetics
  • Werner Syndrome / metabolism
  • Werner Syndrome / pathology
  • Werner Syndrome Helicase

Substances

  • Exodeoxyribonucleases
  • RecQ Helicases
  • WRN protein, human
  • Werner Syndrome Helicase
  • Sirolimus